Humulin I Kwikpen (Isophane) (Insulin Human)

Humulin I Kwikpen is indicated for the management of blood glucose in adults and children with diabetes.

• Type 1 diabetes mellitus requiring basal insulin support.
• Type 2 diabetes mellitus when basal insulin is needed as part of a treatment regimen.
• Adjunct therapy in combination with rapid‑acting insulin for mixed‑meal coverage.
• Use in patients who need a predictable intermediate‑acting insulin profile.

• Humulin I Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose levels. The intermediate‑acting profile results from delayed absorption after subcutaneous injection, providing basal insulin coverage for up to 24 hours.

Like other insulin products, Humulin I Kwikpen may be associated with adverse reactions that vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy at the injection site, presenting as lipoatrophy or lipohypertrophy.
• Transient weight gain due to improved glycemic control.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.

Healthcare professionals should consider several precautions when prescribing Humulin I Kwikpen to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose regularly to avoid hypoglycemia, especially during dose changes.
• Use caution in patients with cardiovascular disease or heart failure, as fluid retention can occur.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Educate patients on proper injection technique and rotation of sites to reduce lipodystrophy.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin I Kwikpen can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that can blunt hypoglycemia warning signs.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require insulin dose adjustments.
• Diuretics, especially thiazides, that can affect electrolyte balance and glucose levels.
• Alcohol consumption, which can unpredictably potentiate or mask hypoglycemia.